The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway

Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice

(2012) Maxime Denis et al.   CIRCULATION

Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with theAPOEp.Leu167del Mutation

(2012) Marie Marduel et al.   HUMAN MUTATION

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

(2012) Evan A Stein et al.   LANCET

The biology and therapeutic targeting of the proprotein convertases

(2012) Nabil G. Seidah et al.   NATURE REVIEWS DRUG DISCOVERY

Clinical aspects of PCSK9

(2011) Bertrand Cariou et al.   ATHEROSCLEROSIS

Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor

(2011) Øystein L. Holla et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

(2011) Paola Lo Surdo et al.   EMBO REPORTS

Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein

(2011) Fen Du et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors

(2011) Øystein L. Holla et al.   JOURNAL OF LIPID RESEARCH

Statin intolerance: Now a solved problem

(2011) P Sikka et al.   Journal of Postgraduate Medicine

The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis

(2010) Jean Davignon et al.   Current Atherosclerosis Reports

A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake

(2010) Yan G. Ni et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

In VivoEvidence That Furin from Hepatocytes Inactivates PCSK9

(2010) Rachid Essalmani et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effects of the Prosegment and pH on the Activity of PCSK9

(2010) Suzanne Benjannet et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain

(2010) Thea Bismo Strøm et al.   MOLECULAR GENETICS AND METABOLISM

Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation

(2009) Steve Poirier et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A new method for measurement of total plasma PCSK9: clinical applications

(2009) Geneviève Dubuc et al.   JOURNAL OF LIPID RESEARCH

PCSK9 as a therapeutic target of dyslipidemia

(2008) Nabil G Seidah   EXPERT OPINION ON THERAPEUTIC TARGETS

Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration

(2008) Ahmed Zaid et al.   HEPATOLOGY

PCSK9: a convertase that coordinates LDL catabolism

(2008) Jay D. Horton et al.   JOURNAL OF LIPID RESEARCH

Molecular basis for LDL receptor recognition by PCSK9

(2008) H. J. Kwon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

(2008) D.-W. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA